GlassScriptPhysician profile
George Bensch
NPI 1508839457
$77,831.70
in general payments reported to CMS, 2019-2025
43 companies · $5,873 in 2025
The $5,873 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $8,971 · 2021: $4,252 · 2022: $4,627 · 2023: $6,911 · 2024: $14K · 2025: $5,873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $4,436 · Travel and Lodging: $1,178 · Education: $314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,025.00 |
| Food and Beverage | $4,435.86 |
| Travel and Lodging | $1,178.25 |
| Education | $314.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $59,623.71 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $5,917.03 | 2019-2023 | Stiolto Respimat |
| Pfizer INC. | $2,649.06 | 2019-2025 | |
| Amgen INC. | $2,403.14 | 2022-2025 | Tezspire |
| Astrazeneca Uk Limited | $1,692.00 | 2019 | |
| Octapharma USA, INC. | $776.62 | 2019-2023 | Cutaquig |
| Regeneron Healthcare Solutions, INC. | $555.68 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $537.04 | 2020-2025 | Hyqvia, Takhzyro, Cuvitru |
| Genzyme Corporation | $530.23 | 2021-2025 | |
| Boehringer Ingelheim International Gmbh | $451.92 | 2020 | |
| Optinose US, INC. | $382.57 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $337.83 | 2019-2025 | |
| Csl Behring | $171.78 | 2020-2025 | Hizentra, Andembry, Haegarda |
| Glaxosmithkline, LLC. | $170.57 | 2023-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Biocryst US Sales Co., LLC | $170.36 | 2021-2025 | Orladeyo |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $164.36 | 2022-2025 | Prolastin-C Liquid, Xembify |
| Sanofi-Aventis U.S. LLC | $154.94 | 2025 | |
| Kaleo, INC. | $148.57 | 2020-2023 | Auvi-Q |
| Shire North American Group INC | $144.82 | 2019 | |
| Abbvie INC. | $127.86 | 2021-2025 | |
| Pharming Healthcare, INC. | $104.92 | 2021-2025 | Ruconest |
| Baxter Healthcare | $86.36 | 2024-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System |
| Ars Pharmaceuticals Operations, INC. | $85.67 | 2025 | Neffy |
| Jubilant Hollisterstier LLC | $70.69 | 2022 | |
| Incyte Corporation | $61.52 | 2022-2025 | Opzelura |
| Teva Pharmaceuticals USA, INC. | $59.53 | 2019-2020 | |
| Greer Laboratories, INC. | $51.47 | 2019 | |
| Galderma Laboratories, L.P. | $27.38 | 2024-2025 | Nemluvio |
| Aimmune Therapeutics, INC. | $26.23 | 2022 | |
| Hikma Pharmaceuticals USA | $24.51 | 2024 | Ryaltris |
| Merck Sharp & Dohme LLC | $23.23 | 2023 | |
| Genentech USA, INC. | $22.14 | 2020 | |
| Hospira, INC. | $18.31 | 2019 | |
| Advanced Respiratory, INC | $16.17 | 2019 | |
| Biocryst Pharmaceuticals, INC. | $15.90 | 2020 | |
| Covis Pharma Gmbh | $15.19 | 2022 | |
| Seqirus USA INC | $12.39 | 2022 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Bensch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.